Evaluation of efficacy and safety profile of tamsulosin in benign prostatic hyperplasia

Praveen R.; Kumar T. N.

doi:10.18203/2319-2003.ijbcp20200186

Authors

Praveen R. Department of Pharmacology, Venkateshwara Institute of Medical Sciences, Gajraula, Uttar Pradesh, India
Kumar T. N. Department of Pharmacology, Sree Narayana Institute of Medical Sciences, Ernakulam, Kerala, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20200186

Keywords:

Benign prostatic hyperplasia, Tamsulosin, Post void residual urine

Abstract

Background: To evaluate the efficacy and safety profile of alpha-1A receptor subtype specific antagonist-tamsulosin in benign prostatic hyperplasia.

Methods: An open label, non-randomised, prospective, single centred study who were visiting urology department with confirmed diagnosis of benign prostatic hyperplasia (BPH) were included in the study. Thirty patients with BPH were prescribed tamsulosin and were followed up to three months. The initial or baseline data collected were identification of the patients such as international prostate symptom score (IPSS), prostate specific antigen, urine analysis, and ultrasonography of prostate including post void residual urine. The patients were followed up to 3 months to measure clinical and laboratory outcomes (IPSS score, post void residual urine, uroflow rates etc.).

Results: In our study, patients receiving tamsulosin 0.4 mg once daily showed a significant improvement in post-void residual urine (PVRU), uroflow rates and IPSS score. The improvements in the above parameters were found to be statistically insignificant at first and third month of follow-up.

Conclusions: In our study, tamsulosin an alpha-1A receptor subtype specific antagonist showed significant improvement in BPH symptoms and the drug was well tolerated.

Metrics

Metrics Loading ...

References

Park CH, Chang HS, Oh BR, Hung KM, Sul CK, Chung SK, et al. Efficacy of low dose tamsulosin on lower urinary tract symptoms of benign prostatic hyperplasia. J Clin Drug Invest. 2004;24(1):41-7.

Marberger M, Horkaway R, Rosette JD. Optimising the medical management of benign prostatic hyperplasia. J Eur Urol. 2004;45:411-9.

Tanaka Y, Naoya M, Itoh N, Sato Y, Takahashi A, Ogura H, et al. Urodynamic effects of terazosin treatment for japanese patients with symptomatic benign prostatic hyperplasia. J Urol. 2002;167:2492-5.

Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Inter. 2005;95(7):1006-12.

Rosette JJ, Mathew PH, Connor SE, Cockett A, Druker BJ. Response of prostate volume and prostate specific antigen to tamsulosin and alfuzosin in men with benign prostatic hyperplasia. J Urol. 1993;9:123-31.

Hannah C, Goa KL. Dutasteride. J Drugs Aging. 2003;20:905-16.

Cockrum PC, Finder SF, Ries AJ, Potyk RP. A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia. J Pharmacoeconomics. 1997;11:550-65.

Praveen R. Tamsulosin turn around. Int J Cur Bio Med Sci. 2011;1(2):39-40.